Dry powder inhalation of colistin sulphomethate in healthy volunteers
| Autor: | P.P.H. Le Brun, de Anne Boer, Daan J Touw, Henderik W. Frijlink, E.M. Westerman, H.G.M. Heijerman |
|---|---|
| Přispěvatelé: | Pharmaceutical Technology and Biopharmacy, Biopharmaceuticals, Discovery, Design and Delivery (BDDD) |
| Jazyk: | angličtina |
| Rok vydání: | 2007 |
| Předmět: |
Oral
Adult Male medicine.medical_specialty Time Factors Pharmaceutical Science Administration Oral Pilot Projects Cystic fibrosis Models Biological Pulmonary function testing Models Reference Values Administration Inhalation medicine Tobramycin Humans Particle Size Lung Antibacterial agent Inhalation business.industry Colistin Inhaler Nebulizers and Vaporizers medicine.disease Biological Dry-powder inhaler Surgery Anti-Bacterial Agents Respiratory Function Tests Anesthesia Administration Feasibility Studies Female Powders business medicine.drug |
| Zdroj: | International Journal of Pharmaceutics, 335(1-2), 41-45. Elsevier Bedrijfsinformatie b.v. |
| ISSN: | 0378-5173 |
| Popis: | Background Pulmonary administration of the antimicrobial drugs colistin sulphomethate and tobramycin has been shown to be effective in slowing down pulmonary deterioration in cystic fibrosis (CF) patients. Both drugs are administered by liquid nebulisation, a technique known to have disadvantages. Dry powder inhalation may be an attractive alternative. We investigated inhalation of colistin sulphomethate dry powder using a newly developed Twincer ® device in healthy volunteers. Methods Eight healthy volunteers inhaled a single dose of 25 mg colistin sulphomethate dry powder each, using the Twincer ® inhaler. The median diameter ( X 50 ) of the dry powder was 1.6 μm ( X 10 = 0.7 μm, X 90 = 3.1 μm), measured by laser diffraction technique. Pulmonary function tests were performed before, 5 and 30 min after inhalation. Serum samples were drawn at t = 15 min, 45 min, 1.5 h, 2.5 h, 3.5 h, 5.5 h, 7.5 h and 24 h after inhalation. Results The colistin sulphomethate dry powder inhaler was well tolerated: no clinically relevant effect on FEV 1 was observed nor did the volunteers experience adverse effects. Conclusion Dry powder inhalation of colistin sulphomethate using the Twincer ® inhaler is well tolerated by healthy volunteers. A pilot study in cystic fibrosis patients is therefore considered safe in developing a dry powder inhalation of colistin for everyday CF treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect